Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
LIXTE Biotechnology Holdings, Inc. a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer I...
Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...
Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC a...
OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments wi...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with pa...
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA res...
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC por...
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is appro...
Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOB...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...
© 2024 Biopharma Boardroom. All Rights Reserved.
